RE:RE:SunPharma failure on USA Absorica market share In your post did you mean CPH should use it's own sales staff to sell Absorica and keep the 7.5% payout to Sun Pharma? I'm not sure what the agreement with Sun Pharma/Ranbaxy specifically states but it's pretty standard to have revenue milestone within, that have to be obtained to maintain exclusivity. As they are not hitting those growth numbers it's a possibility Cipher will use it's new US sales force to sell Absorica. I wouldn't be surprised if it's been the plan all along and Sun Pharma realizes this so are not commiting new efforts to selling/marketing Absorica. I also find it odd that Cipher recently made a new hire to manage the Sun Pharma relationship rather this not just handing that responsibility to the person in charge of the Ranbaxy relationship, since they are one company now. I think it's because the new guy will be the new internal head of sales for Absorica using Cipher's sales force. I am speculating, but it would make sense.
Regardless I'm personally happy that Absorica numbers were flat as retail investors are focused on that so it created a panic selloff yesterday and allowed me do to some 16% off discount shopping. Don't worry, Absorica number will improve (and other products as well) now that the Innocutis integration is complete as focus will return back to product marketing/sales and execution.